Therapy Type: Small Molecule (timeline)
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Pfizer lists PF-05251749 in its November 2016 pipeline as being a Phase 1 compound for Alzheimer's disease, but has not disclosed a mechanism of action. It is an oral compound.
In 2015, Pfizer conducted a single-site, single-ascending-dose study in 32 healthy volunteers, assessing its propensity to induce movement disorders and affect mood and fatigue, as well as pharmacokinetics and exposure in CSF.
In March 2016, the company started an ascending-multiple-dose study of 50 to 900 mg daily of this compound in 96 healthy elderly volunteers at two sites in Florida. This trial also assesses suicidality and melatonin production, and expands the number of pharmacokinetic measures. One arm administers PF-05251749 together with melatonin.
For all trials of this drug, see clinicaltrials.gov.
No Available Further Reading